Techmeme, citing Axios, reports that RAISE France and Orange Ventures co-led the French pharma software startup’s round, bringing its total funding to €36M.
Biolevate raised €30M to scale its life sciences AI platform globally, The SaaS News reports. Techmeme, citing Axios, says RAISE France and Orange Ventures co-led the Series A, which brings the French startup’s total funding to €36M.
4.4K
2 Sources, first seen ago
—
Not ranked yet
—
Not ranked yet
French pharma software startup Biolevate has raised a €30 million Series A, according to an Axios Pro report that attributes the news to CEO Joël Belafa.
The round brings fresh backing to a young company in the life-sciences software market. Biolevate describes its work around automation; Orange says its product is intended to automate complex processes and help bring medicines and other life-sciences products to market faster.
Orange Ventures confirmed it invested as part of the latest round. That public confirmation establishes its participation, while the Axios report supplies the round amount and stage. Neither available source provides a complete public investor list, valuation or detailed allocation of the new capital, so those details are not treated as established here.
For Biolevate, the financing puts the practical test on whether software and AI-assisted automation can reduce the administrative and research friction around drug-development work without becoming another disconnected tool in an already crowded enterprise stack.
Not enough discussion yet.
No sentiment analysis available yet.
Not enough discussion yet.
No sentiment analysis available yet.
